Bolt Biotherapeutics
Shahid Khan currently serves as Lead - Bioconjugation at Asieris Pharmaceuticals since May 2023. Prior experience includes working as a Senior Scientist II at Abbott from August 2021 to April 2023, where responsibilities involved the preparation and characterization of various antibody conjugates using analytical and biophysical methods. Shahid Khan was also a Postdoctoral Associate at New York University from August 2018 to July 2021, focusing on protein characterization and diversity initiatives, and held a similar position at the University of Pittsburgh School of Medicine from April 2015 to July 2018, studying HIV-1 protease. Educational qualifications include a PhD in Biochemistry from Ecole normale supérieure, a Master's degree in Medical Biosciences from Linköping University, and a Bachelor of Pharmacy from the University of the Punjab.
This person is not in any teams
Bolt Biotherapeutics
7 followers
Bolt Biotherapeutics, Inc., based in the San Francisco Bay Area, is a publicly-traded biotechnology company developing Boltbody™ Immune-stimulating Antibody Conjugates (ISAC), a new class of immuno-oncology therapeutics that have eliminated tumors following systemic administration in preclinical studies and results in the development of immunological memory, which may lead to more durable clinical responses for patients.